New combo pill aims to simplify diabetes care

NCT ID NCT04670666

Recruiting now Disease control Sponsor: EMS Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests a new combination pill called Madalena association for people with type 2 diabetes whose blood sugar is not well controlled with two other diabetes drugs. About 270 adults will receive either the new combo pill, standard medications, or placebos to see which works best and is safest. The main goal is to lower HbA1c levels, a key measure of blood sugar control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Madalena association (a combination pill of multiple diabetes drugs)
What this could lead to: If it works, this could offer a simpler, more effective pill option for people with type 2 diabetes who need better blood sugar control.
What could go wrong: This is a Phase 3 trial, but results may not apply to everyone. Side effects are possible, and the new combo may not be significantly better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

EMS
RECRUITING

Hortolândia, São Paulo, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.